Introduction
Gastrointestinal (GI) endoscopies are critical diagnostic procedures that examine the inner lining of the digestive tract. This minimally invasive treatment includes inserting a flexible tube with a camera and light source into the mouth or rectum, letting doctors see and assess the esophagus, stomach, small intestine, and colon [1]. Endoscopies are used to diagnose various GI disorders, including ulcers, polyps, inflammation, bleeding, and cancer. Furthermore, they allow therapeutic procedures like polyp excision, hemorrhage management, and stent implantation [2]. In the general population, they are regarded as reasonably safe, with the incidence of adverse events (AE) increasing with procedure complexity. With advancements in technology and techniques, GI endoscopies have become safer, more efficient, and increasingly integral to providing precise diagnoses and treatments for patients with GI disorders [3,4].
Severe adverse events (SAEs) after colonoscopy include a variety of possible problems. These include GI perforation, which may result from mechanical forces against the bowel wall, barotrauma, or a direct result of therapeutic procedures. Early symptoms include persistent abdominal pain and abdominal distention [5]. Another prominent consequence is GI bleeding, which occurs when polyps are removed during a colonoscopy or when the colon lining is traumatized, necessitating bleeding management procedures [6]. Although rare, sedation-related cardiopulmonary problems such as respiratory depression or cardiovascular events might occur, emphasizing the significance of meticulous monitoring throughout the treatment. Furthermore, post-polypectomy syndrome, which is characterized by stomach discomfort, fever, and leukocytosis, can develop following polyp removal, but rarely. Infection, albeit uncommon, is a possible concern following colonoscopy, especially if correct sterile methods are not used [7]. Patients should be educated about these potential consequences and closely monitored by healthcare professionals to reduce risks and guarantee prompt treatment if SAEs occur.
Indeed, the risk factors for SAEs after colonoscopy can be complex, involving both patient- and procedure-related characteristics. Patient-related risk factors include advanced age since elderly people may have weaker colonic walls and are more susceptible to problems [8,9]. The female gender has also been linked to a slightly greater incidence of SAEs, either due to anatomical variations or hormonal reasons [10]. Comorbidities such as cardiovascular disease, diabetes, or chronic renal disease might increase the risk of problems during and after the treatment. Medications, including anticoagulants and antiplatelet medications, can increase the risk of bleeding during polypectomy [9].
Procedure-related risk factors include the reason for colonoscopy, with emergency procedures posing a greater risk than elective ones. Prolonged procedure times, generally owing to complicated anatomy or difficult polyp removal, might increase the risk of adverse outcomes [11]. The performance of polypectomy itself is a substantial risk factor, especially if big or numerous polyps are removed, as this increases the likelihood of bleeding or perforation. Furthermore, the size and position of polyps are important, with bigger or sessile polyps in difficult places offering a higher risk [12].
Underweight individuals, defined as having a body mass index (BMI) of less than 18.5, are a vulnerable demographic population [13]. When regular endoscopic treatments are required, these people frequently confront specific obstacles and considerations due to their decreased body weight and possible underlying health issues. Patients with LBMI are predisposed to sharp angulations during the endoscopic encounter, thus increasing the likelihood of trauma. The patients are also associated with difficult colonic intubation, longer colon, and more chances of looping, thus increasing the overall contact time of the endoscope with the mucosal surface and increasing the shear stress within the lumen [14,15].
Sedation and anesthesia during endoscopic operations are particularly concerning for underweight patients. Their decreased body weight may necessitate cautious medication dose adjustments to avoid over-sedation or unpleasant responses. Furthermore, underweight people may be more vulnerable to aspiration during sedation due to a lack of respiratory reserve and muscular mass [7,16].
Healthcare practitioners performing endoscopic operations on underweight people should be aware of these risks and take necessary precautions to guarantee their patients' safety and well-being. This may involve close monitoring during and after the treatment, customized sedation regimens, and post-procedure nutritional assistance, if necessary. Furthermore, a thorough pre-procedure examination and optimization of nutritional status and general health may assist in reducing risks and enhancing results for underweight patients having endoscopic operations. So, the current study aimed to evaluate whether post-endoscopy SAEs are more common in patients with low BMI and find risk factors for serious adverse outcomes in patients from Saudi Arabia.
Materials and methods
Study type and design
A single-center study was conducted on patients visiting the internal medicine department from April 2023 to November 2023. Patients had endoscopic procedures for different medical purposes. All patients were adults (age ≥ 18 years at the time of endoscopic interventions) and had an endoscopic intervention. Patients were divided into two groups: Group I, which had a low BMI (BMI ≤ 18.5%), and Group II, which is the control group (18.5 ≤ BMI ≤ 30%).
Both groups were matched with regard to age, gender, comorbid disease, type of endoscopy, inflammatory bowel disease (IBD) diagnosis, a diagnosis of malignant disease of any kind, use of anticoagulation drugs (for a week pre-procedure), and any prior abdominal or pelvic surgery.
The sample size was calculated as previously described by Kadam and Bhalerao [17]. So, 398 patients were recruited from one medical center in Saudi Arabia.
Inclusion criteria
Males and females aged 18 years or older at the time of endoscopic interventions and all patients with BMIs lower than 30% were included in the study. These patients were then divided into a low BMI (LBMI) group, defined as BMI ≤ 18.5%, and a sample comparator group (normal-overweight BMI range, NBMI), which included patients with BMIs higher than 18.5% and lower than or equal to 30%. These patients underwent endoscopic intervention from April 2023 to November 2023.
Exclusion criteria
Males and females aged less than 18 years at the time of endoscopic interventions and patients with a BMI value > 30% were excluded from the study.
Data collection
Data were collected from the medical records of the participating center. It was defined as the information collected and generated by a healthcare provider to provide healthcare for the personal benefit of the patient, where the information within medical records has clinical validity and utility.
Data were collected and extracted from original data sources anonymously on a patient-level basis and then combined to conduct statistical analysis. These data included age, gender, weight, height, BMI, comorbidities, treatments, laboratory results pre-endoscopy, endoscopy interventions, endoscopy indications, endoscopy diagnosis, and post-endoscopy complications.
Statistical analysis
The data gathered underwent organization, tabulation, and statistical analysis using SPSS software version 22 (IBM Corp., Armonk, NY). Mean and standard deviation (SD) calculations were conducted for quantitative data. Whenever relevant, one-way ANOVA was employed to compare the means of categories of two or more variables to determine any statistical evidence between the two groups. Qualitative data were summarized through calculations of frequency and percentage distributions. A significance threshold of p ≤ 0.05 was applied to interpret the results of significance tests.
Results
In the present study, the medical records of 398 patients who underwent abdominal endoscopy were investigated. The demographic and clinical characteristics are listed in Table 1. Among them, 108 patients had a lower BMI (LBMI), while 209 had normal BMI values (control). Patients in the LBMI group had significantly lower ages (39.1 ± 19.7 years) than those in the control group (50.1 ± 16.6 years) (p < 0.001). Statistically, none of the collected data followed a normal distribution regarding the BMI categories. The statistical analysis revealed significant variance between both groups regarding gender (p = 0.013).
Table 1
Demographic and clinical characteristics of the studied patients
# One-Way ANOVA (POSTHOC = LSD ALPHA [0.05]).
* Significant at p < 0.05.
BMI: Body mass index; Hb: Hemoglobin; WBC: White blood cells; Plt: Platelets; sCr: Serum creatinine; Alb: Albumin; CKD: Chronic kidney disease; CVA: Cerebrovascular accident (stroke); CVD: Cerebrovascular disease; COPD: Chronic obstructive pulmonary disease; IBD: Inflammatory bowel disease; OR: Odds ratio; CI: Confidence of intervals; PPI: Proton pump inhibitors; LSD: Least significant difference.
Variables | LBMI group (N = 108) | Control group (N = 290) | P-value# | OR | 95% CI | ||
Low | Up | ||||||
Age (years) | 39.1 ± 19.7 | 50.1 ± 16.6 | <0.001* | ||||
Weight (kg) | 47.4 ± 5.5 | 64.3 ± 9 | <0.001* | ||||
Height (cm) | 163.1 ± 6 | 162.8 ± 7.5 | 0.688 | ||||
BMI (%) | 17.7 ± 0.9 | 24.2 ± 2.5 | <0.001* | ||||
Gender | Male | 49 (45%) | 172 (59.3%) | 0.013* | 0.57 | 0.37 | 0.89 |
Female | 59 (54%) | 118 (40.7%) | |||||
Laboratory results | Hb (g/dL) | 12.2 ± 2 | 12.6 ± 2.1 | 0.069 | |||
WBC (×109/L) | 6.6 ± 1.9 | 6.6 ± 1.9 | 0.961 | ||||
Plt (×109/L) | 291.9 ± 90.9 | 283.5 ± 91.1 | 0.414 | ||||
sCr (µmol/L) | 85.5 ± 74.5 | 91.9 ± 71.3 | 0.435 | ||||
Alb (g/L) | 35.8 ± 6.4 | 38.1 ± 4.7 | <0.001* | ||||
Total protein (g/L) | 70.4 ± 6.9 | 73.3 ± 5.1 | <0.001* | ||||
Comorbidities | None | 48 (44.4%) | 132 (45.7%) | 0.827 | 0.95 | 0.61 | 1.48 |
CKD | 14 (13%) | 41 (14.1%) | 0.763 | 1.1 | 0.58 | 2.12 | |
CVA/Dementia | 10 (9.3%) | 11 (3.8%) | 0.03* | 0.39 | 0.16 | 0.94 | |
CVD | 6 (5.6%) | 27 (9.3%) | 0.228 | 1.75 | 0.7 | 4.35 | |
COPD | 0 (0%) | 1 (0.3%) | 0.542 | 1 | 1 | 1.01 | |
Connective tissue diseases | 6 (5.6%) | 13 (4.5%) | 0.656 | 0.8 | 0.3 | 2.16 | |
Liver disease | 6 (5.6%) | 19 (6.6%) | 0.717 | 1.19 | 0.46 | 3.07 | |
Diabetes | 28 (25.9%) | 121 (41.7%) | 0.004* | 2.05 | 1.25 | 3.34 | |
Malignancy | 3 (2.8%) | 11 (3.8%) | 0.626 | 1.38 | 0.38 | 5.04 | |
IBD | 17 (15.7%) | 15 (5.2%) | 0.001* | 0.29 | 0.14 | 0.61 | |
Previous abdominal pelvic surgery | 18 (16.7%) | 62 (21.4%) | 0.697 | ||||
Treatment | None | 48 (44.4%) | 135 (46.7%) | 0.687 | 0.91 | 0.89 | 1.42 |
Chemotherapy | 3 (2.8%) | 10 (3.4%) | 0.739 | 1.25 | 0.34 | 4.63 | |
Biological | 17 (15.7%) | 15 (5.2%) | 0.001* | 0.29 | 0.14 | 0.61 | |
PPI | 39 (36.1%) | 126 (43.3%) | 0.187 | 1.36 | 0.86 | 2.15 | |
Antibiotics | 8 (7.4%) | 11 (3.8%) | 0.133 | 0.49 | 0.19 | 1.26 | |
Steroids | 18 (16.7%) | 20 (6.9%) | 0.003* | 0.37 | 0.19 | 0.73 | |
Anticoagulants | 7 (6.5%) | 22 (7.6%) | 0.707 | 1.18 | 0.49 | 2.86 | |
Feeding tube | 5 (4.6%) | 2 (0.7%) | 0.008* | 0.14 | 0.03 | 0.75 |
The history of clinical records before the endoscopy procedure comprised three categories: comorbidities, laboratory results, and prescribed treatments. LBMI patients had significantly lower levels of albumin (35.8 ± 6.4 g/L) and total protein (70.4 ± 6.9 g/L) than control group patients (p < 0.001). Most patients did not have any records of comorbidities (LBMI: 44.4% and control: 45.7%). The recorded associated comorbidities included chronic kidney disease (CKD), cerebrovascular accident (CVA), cerebrovascular disease (CVD), chronic obstructive pulmonary disease (COPD), diabetes (DM), liver diseases, connective tissue diseases, and IBD. More cases of control group patients had different types of diabetes: 121 (41.7%) compared to 28 (25.9%) patients in the LBMI group with a high odds ratio (OR = 2.05, 95% CI = 1.25-3.34, p = 0.004). These types included DM type 1 (5 [1.3%] and 4 [1%]), DM type 2 (22 [5.5%] and 117 [29.4%]), and diabetic ketoacidosis (DKA) (5 [1.3%] and 4 [1%]) in the LBMI group as well as DM type 2 (1 [0.3%] and 0 [0%]) in the control group, respectively. The results recorded one case of colorectal cancer (CRC), chronic myelogenous leukemia (CML), and pancreatic cancer in the LBMI group, whereas the control group had six cases of CRC and one case of hepatocellular carcinoma (HCC). The data on malignancy did not reveal any significant variation between both groups (p = 0.626). The percentage of IBD cases was significantly higher in the LBMI (15.7%) than in the control (5.2%) groups (OR = 0.29, 95% CI = 0.14-0.61, p = 0.001) (Table 1).
At admission, some patients (54%) had specific treatments, mainly for the comorbidities mentioned above. These treatments included chemotherapies, biological therapies, proton pump inhibitors (PPI), antibiotics, steroids, anticoagulants, or tube feeding. Biological therapies, steroids, and feeding tubes were significantly reported for the LBMI patients as 15.7%, 4.6%, and 16.7% compared to 5.2%, 0.7%, and 6.9% of the control (p < 0.05), respectively. None of the other treatments were significantly predominant in any of the tested groups (Table 1).
Before admission, different types of endoscopy were used in the studied patients, as stated in medical reports. The endoscopic interventions included esophagogastroduodenoscopy (EGD), endoscopic retrograde cholangiopancreatography (ERCP), percutaneous endoscopic gastrostomy (PEG), colonoscopy, sigmoidoscopy, or a combined procedure. Other reasons included mucosal breaching (biopsy/polypectomy during the procedure), band ligation, stent insertion, or therapy injection. In about 41.7% of LBMI and 37.2% of the control group patients' medical records, no clear intervention was mentioned. Except for PEG (OR = 0.175, 95% CI = 0.05-0.59, p = 0.004), none of the above-mentioned procedures had a significant majority in both groups. About 7.4% of the LBMI underwent PEG compared to 1.7% of the control group (Table 2).
Table 2
Endoscopic Intervention data according to the BMI category of the studied patients
# One-Way ANOVA (POSTHOC = LSD ALPHA [0.05]).
* Significant at p < 0.05.
BMI: Body mass index; EGD: Esophagogastroduodenoscopy; ERCP: Endoscopic retrograde cholangiopancreatography; PEG: Percutaneous endoscopic gastrostomy; LSD: Least significant difference.
Variables | LBMI (N = 108) | Control (N = 290) | P-value# | OR | 95% CI | |
Lower | Upper | |||||
No intervention | 45 (41.7%) | 108 (37.2%) | 0.244 | 0.83 | 0.53 | 1.3 |
EGD | 51 (47.2%) | 133 (45.9%) | 0.448 | 0.95 | 0.61 | 1.47 |
Colonoscopy | 41 (38%) | 122 (42.1%) | 0.266 | 1.19 | 0.75 | 1.87 |
ERCP | 3 (2.8%) | 15 (5.2%) | 0.232 | 1.91 | 0.54 | 6.73 |
PEG | 8 (7.4%) | 4 (1.4%) | 0.004* | 0.175 | 0.05 | 0.59 |
Combined procedure | 3 (2.8%) | 15 (5.2%) | 0.232 | 1.91 | 0.54 | 6.73 |
Sigmoidoscopy | 2 (1.9%) | 1 (0.3%) | 0.18 | 0.18 | 0.02 | 2.04 |
Polypectomy | 7 (6.5%) | 19 (6.6%) | 0.592 | 1.01 | 0.41 | 2.48 |
Biopsy | 53 (49.1%) | 147 (50.7%) | 0.431 | 1.07 | 0.69 | 1.66 |
Brand ligation | 2 (1.9%) | 5 (1.7%) | 0.609 | 0.93 | 0.18 | 4.87 |
Stent insertion | 3 (2.8%) | 4 (1.4%) | 0.288 | 0.49 | 0.11 | 2.22 |
Injection therapy | 0 (0%) | 0 (0%) | - | - | - | - |
Several types and indications were reported in the history of past-abdominal pelvic surgeries in some patients (20.1%) (Figure 1). These included post-lap chole, post-sleeve, appendectomy, bowel resection, colon resection, anastomosis, C-section, hernia repair, hemicolectomy, hemorrhoidectomy, hysterectomy, intestinal resection, anastomosis, left hemicolectomy, right hemicolectomy, nephrectomy, colectomy, post renal transplant, sleeve gastrectomy, and sigmoid resection. There was insignificant variation between the two BMI groups (p = 0.452).
Figure 1
Bar charts of past-abdominal pelvic surgery in the studied patients
After admission, all patients underwent endoscopy procedures to investigate and diagnose different complications. The procedure was completed in 383 (96%) of patients, whereas only 15 (4%) had some complications because of poor preparation (OR = 0.66, 95% CI = 0.18-2.39). As shown in Table 3, endoscopy was indicated because of abdominal pain, anemia, sigmoid colon thickness/mass, diarrhea, bloody diarrhea, esophageal dilation, vomiting, lower or upper GI bleeding, dyspepsia, dysphagia, liver cirrhosis, obstructive jaundice, odynophagia, occult blood positive, a partial colectomy, food impaction, or just screening for feeding, follow-up, or investigation. There was no significant variation in the endoscopy indication between the two BMI groups (Figure 2).
Table 3
Endoscopic indication data according to the BMI category of the studied patients
# One-Way ANOVA (POSTHOC = LSD ALPHA [0.05]).
BMI: Body mass index; GI: Gastrointestinal; LSD: Least significant difference.
Variables | LBMI (N = 108) | Control (N = 290) | P-value# |
Abdominal pain | 6 (5.6%) | 5 (1.7%) | 0.225 |
Anemia | 1 (0.9%) | 16 (5.5%) | |
Sigmoid colon thickness/Mass | 2 (1.9%) | 3 (1%) | |
Diarrhea | 7 (6.5%) | 17 (5.9%) | |
Bloody diarrhea | 4 (3.7%) | 15 (5.2%) | |
Esophageal dilation | 0 (0%) | 1 (0.3%) | |
Vomiting | 1 (0.9%) | 1 (0.3%) | |
Lower GI bleeding | 4 (3.7%) | 22 (7.6%) | |
Dyspepsia | 38 (35.2%) | 86 (29.7%) | |
Dysphagia | 2 (1.9%) | 8 (2.8%) | |
Liver cirrhosis | 5 (4.6%) | 5 (1.7%) | |
Obstructive jaundice | 5 (4.6%) | 13 (4.5%) | |
Upper GI bleeding | 4 (3.7%) | 8 (2.8%) | |
Odynophagia | 0 (0%) | 2 (0.7%) | |
Occult blood positive | 12 (11.1%) | 20 (6.9%) | |
Partial colectomy | 0 (0%) | 2 (0.7%) | |
Food impaction | 0 (0%) | 2 (0.7%) | |
Screening (for feeding, follow-up, or investigation) | 17 (15.7%) | 64 (22.1%) |
Figure 2
Bar charts of endoscopy indications in the studied groups
Regarding endoscopy diagnosis, more accurate outcomes were denoted for patients of the two groups. Endoscopy findings were normal only in 16 (14.8%) and 49 (16.9%) of the LBMI and control groups, respectively, which indicated some asymptomatic disorders or previous misdiagnosis. The most common diagnostic findings were gastritis and internal hemorrhoid in 8.3% of the LBMI patients, followed by colonic polyps, Crohn’s disease, and esophageal varices (5.6%). In the control group patients, the most common findings were internal hemorrhoid (6.9%), colonic polyp (5.5%), GERD (5.5%), H. pylori (4.8%), gastritis (4.5%), Common bile duct (CBD) stones (4.5%), and nodular gastritis (3.4%) (Appendix table).
No post-endoscopy complications were reported in both groups. The screened complications were GI bleeding, aspiration pneumonia, systemic infection, GI perforation, or over-sedation. A comparison of these reports and outcomes confirmed a robust endoscopy technique used at the studied center, which avoided the most known risk factors for LBMI patients.
Discussion
The present study sheds light on the relationship between LBMI and clinical outcomes after abdominal endoscopic operations. A review of medical records from 398 individuals having endoscopy revealed numerous noteworthy findings involving demographic features, clinical profiles, procedural details, and post-endoscopy outcomes.
One of the most notable results was that LBMI patients were much younger than those in the control group. This study implies that younger people may be more vulnerable to variables that contribute to LBMI, such as chronic illnesses or dietary inadequacies, which could affect their risk profile for endoscopic treatments. A previous study showed that females with a BMI < 19 or males with a BMI < 20 were at high risk of primary vascular regulation, Flammer syndrome, systemic hypoxia, eye disorders, depression, multiple sclerosis, xerostomia, chronic inflammations, and a predisposition to cancer; however, those were not recorded in the current study [18]. In a cross‐sectional study conducted by Katanoda et al., they found that female adults at younger ages of 18 years with low BMI were at higher risk of diabetes with a significantly high odds ratio of 2.25 and 95% CI: 1.01-4.99 [19].
Furthermore, the current study found disparities in laboratory markers between the two BMI groups, with lower amounts of albumin and total protein in individuals with LBMI. Furthermore, LBMI patients suffered from CVA and connective tissue diseases more than patients with a higher BMI. These biochemical markers reflect nutritional status and overall health, emphasizing the susceptibility of LBMI patients to malnutrition-related problems. In the study conducted by Streng et al., LBMI patients had higher natriuretic peptide levels and lower levels of uric acid, pro-adrenomedullin, creatinine, sodium, and bicarbonate [20].
In the current study, comorbidities were distributed differently among the groups, with diabetes mellitus being more common in the control group. Interestingly, IBD was more common among LBMI patients, implying a link between BMI and GI pathology. Several studies highlighted the relationship between LBMI and IBD factors, such as morbidity, complications, prognosis, disease stages, and available therapy. It was reported before that IBD patients usually had an LBMI [21], which increases the risk of Crohn’s disease [22,23]. The unequal distribution of specific comorbidities emphasizes the significance of taking underlying medical problems into account when calculating the likelihood of adverse outcomes following endoscopic treatments.
Treatment techniques vary between BMI groups, with LBMI patients using more biological treatments, steroids, and feeding tubes. These therapies may represent the treatment of underlying diseases such as IBD or malnutrition, which might affect procedure results. Furthermore, endoscopic interventions vary per patient, with the most prevalent procedures being esophagogastroduodenoscopy (EGD) and colonoscopy. Importantly, no significant variations in the distribution of endoscopic indications were seen across the BMI groups, suggesting that the choice to conduct endoscopy was unaffected by BMI status. Endoscopy detected a variety of GI diseases, including gastritis, colonic polyps, Crohn's disease, and esophageal varices. Importantly, no post-endoscopy problems were observed in either BMI group, demonstrating that the research center's endoscopic procedures are generally safe.
Against our findings, previous studies demonstrated that LBMI patients, who underwent EGD, PEG, and colonoscopy, were at high risk of endoscopy-related SAEs, such as GI bleeding, perforation, and aspiration pneumonia [15,24]. Another study from Milton Keynes University Hospital, UK, showed that LBMI patients had a high incomplete colonoscopy rate, particularly for the sigmoid colon, which might be because of patient intolerance and old age (>40 years) [25]. Similar to our findings, a cohort study from California, USA, showed that LBMI did not increase the incidence or severity of post-ERCP pancreatitis, a common complication after an endoscopic procedure [26]. These discrepancies may indicate variations in medical center facilities and the efficiency of medical teams in managing post-endoscopic complications.
The study was based on retrospective data collection. One of the most significant drawbacks of the retrospective was misclassification/ascertainment bias. Retrospective studies rely on data that were recorded into a clinical database but not collected for study. The investigator had little control over the type and quality of the gathered variables, and they could not guarantee that the features of interest were correctly and reliably documented. Furthermore, certain variables that may influence the conclusion may not have been captured at all. The patient records are likely to be incomplete in various ways and may contain incorrect data.
Conclusions
The link between low BMI and post-endoscopy SAEs emphasizes the significance of individualized risk assessment and mitigation techniques in this vulnerable patient population. The current study revealed that abdominal pain, diarrhea, dyspepsia, and positive occult blood are the most common indications for LBMI patient's endoscopy. Also, colonic polyps, Crohn’s disease, esophageal varices, gastritis, and internal hemorrhoids were the most common diagnostic pathologies for LBMI patients. Pre-procedural optimization, such as nutritional support and hydration, may enhance results in those with a low BMI, who are undergoing endoscopy. Furthermore, careful choice of endoscopic procedures and equipment as well as close monitoring during and after the surgery are required to reduce the chance of adverse effects. The current study was limited to a small sample size from a single medical center. So, future research should concentrate on prospective studies with larger sample sizes or multiple medical centers to corroborate these findings and identify strategies to lower post-endoscopy problems' prevalence in patients with low BMI. Overall, the findings of this study help us comprehend the complicated interplay between BMI, clinical features, and outcomes after abdominal endoscopy. While low BMI may be linked with specific risk factors and comorbidities, thorough pre-procedural evaluation and adequate patient care can significantly reduce the risk of AE and provide the best possible operative results.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Copyright © 2024, Al-Hagawi et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Gastrointestinal (GI) endoscopies are essential for detecting and treating various digestive tract problems. While typically safe, these treatments can entail the risk of severe adverse events (SAEs), especially in individuals with a low body mass index (BMI). The current study aimed to evaluate whether post-endoscopy SAEs are more common in patients with low BMI and find risk factors for serious adverse outcomes in Saudi Arabian patients from Khamis Mushait, Aseer region, Saudi Arabia. The data of 398 adult patients with abdominal endoscopies between April and November 2023 were analyzed. Patients were divided into two groups: low BMI (BMI ≤ 18.5) and control (18.5 ≤ BMI ≤ 30). They were matched for age, gender, comorbidities, endoscopy type, and other pertinent characteristics. Low-BMI patients (Group I, n = 108) were substantially younger and had lower levels of albumin and total protein than the control group (Group II, n = 209). Comorbidities varied between groups, with diabetes mellitus more prevalent in Group II and inflammatory bowel disease (IBD) more commonplace in Group I. Treatment options also differed, with Group I receiving more biological treatments, steroids, and feeding tubes. Endoscopic procedures and indications were comparable among groups, with no significant variations in post-endoscopy complications. The endoscopy results varied from gastritis to colon malignancy, with no SAEs recorded in either group. Unlike earlier findings, this study found no higher incidence of SAEs in low-BMI individuals having abdominal endoscopy. This might be because of the restricted guidelines of different medical authorities, including clear informed consent that illustrates any risks, benefits, alternatives, sedation plan, and potential diagnostic or therapeutic interventions. Also, professional endoscopists and consultants who ensure adequate visualization of the GI mucosa, using mucosal cleansing and insufflation as necessary, should avoid any risk of abdominal hemorrhage. These findings highlight the significance of personalized risk assessment and pre-procedural optimization, including nutritional assistance, in this patient population. More prospective research with larger sample sizes is needed to validate these findings and create targeted techniques for improving outcomes in individuals with a low BMI having endoscopic operations.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer